TRADING UPDATES: CML plans AIM move; IronRidge to demerge gold assets
TRADING UPDATES: CML plans AIM move; IronRidge to demerge gold assets
Read moreWed, 14th Jul 2021 09:02
TRADING UPDATES: CML plans AIM move; IronRidge to demerge gold assets
Read more(Sharecast News) - Diagnostics and cancer therapies developer Avacta Group updated the market on its CE-mark submission for its 'AffiDX' SARS-CoV-2 antigen lateral flow test for professional use.
Read moreAvacta still waiting on response from UK regulator over Covid test
Read more(Sharecast News) - Cancer therapies and diagnostics developer Avacta Group responded to speculation around the CE-mark submission for its SARS-CoV-2 antigen lateral flow test on Friday.
Read moreIN BRIEF: Avacta to sell Covid-19 test in UK in "coming days"
Read moreAvacta sees Covid-19 tests driving earnings after reporting 2020 loss
Read more(Sharecast News) - Diagnostics and cancer therapies developer Avacta announced positive data from the clinical validation of its 'AffiDX' SARS-CoV-2 antigen lateral flow test on Tuesday.
Read moreIN BRIEF: Avacta's rapid Covid-19 test is 98% sensitive in trial
Read moreAIM WINNERS & LOSERS: Warpaint tops outlook; Avacta's Covid test works
Read moreUK earnings, trading statements calendar - next 7 days
Read moreIN BRIEF: Avacta in global Affimer distribution agreement with Abcam
Read more(Sharecast News) - Cancer therapies and diagnostics developer Avacta Group has entered into a global distribution agreement with Abcam, it announced on Tuesday, to sell its recently-developed SARS-CoV-2 research 'ELISA Affimer' reagents.
Read moreEXECUTIVE CHANGES: Ten Entertainment, Emmerson chairs step down
Read moreIN BRIEF: Avacta Group signs diagnostic licensing deal with Biokit
Read more(Sharecast News) - Cancer therapy and diagnostics developer Avacta has entered into a licence agreement with Werfen subsidiary Biokit, it announced on Tuesday, to incorporate 'Affimer' reagents into a Biokit in-vitro diagnostic product.
Read more